Semaglutide News and Research

Latest Semaglutide News and Research

GLP-1 weight loss drugs leave users low on key nutrients, study finds

This study assessed nutrient intake in adults using GLP-1 receptor agonists (GLP-1RAs) and found widespread deficiencies in essential vitamins and minerals. Despite appetite suppression and weight loss benefits, most participants exceeded fat intake recommendations and failed to meet protein and micronutrient needs.

14 May 2025

New approach directly combats the progression of Alzheimer’s and ALS

Scientists at Northwestern University have developed a new approach that directly combats the progression of neurodegenerative diseases like Alzheimer's disease and amyotrophic lateral sclerosis (ALS).

14 May 2025

Animal research reveals metabolic differences between tirzepatide and semaglutide

New animal research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May), reveals distinct metabolic adjustments to tirzepatide and semaglutide treatment, with tirzepatide temporarily increasing energy expenditure and semaglutide initially reducing energy expenditure.

14 May 2025

Once-daily oral treatment shows positive results in first human study for obesity treatment

A first-in-human study of an investigational once-daily oral treatment for obesity (SYNT-101) demonstrated positive preliminary data for the safe and effective redirection of nutrient absorption into the lower intestine, the weight loss and metabolic management mechanism behind gastric bypass surgery.

14 May 2025

Hormone FGF21 reverses fatty liver disease by signaling the brain

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works primarily by signaling the brain to improve liver function.

13 May 2025

Online obesity clinic achieves clinical trial-level weight loss with lower semaglutide doses

New research being presented at this year's European Congress on Obesity (ECO 2025) has found that patients of an online obesity clinic achieved similar weight loss to that reported in clinical trials – but with less than half the medication.

12 May 2025

Early cardiovascular benefits of semaglutide seen within months in SELECT trial

Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or obesity who have pre-existing cardiovascular disease but not diabetes, according to a secondary analysis of the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial from the same international author team being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain.

12 May 2025

Study shows cardiovascular benefits of GLP-1RAs in patients following bariatric surgery

Medications like semaglutide and liraglutide may help to reduce the risk for heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults with obesity and diabetes following bariatric surgery who did not achieve sufficient weight loss and diabetes control, according to new research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain.

12 May 2025

GLP-1 drugs linked to significant BMI reduction in children with severe obesity

Children who are living with severe obesity are more likely to experience a clinically relevant change in BMI when GLP-1 agonist drugs form part of their treatment, new research being presented at year's European Congress on Obesity (ECO 2025) suggests.

12 May 2025

Tirzepatide outperforms semaglutide for weight loss in people without diabetes

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in adults with obesity but without diabetes. Over 72 weeks, tirzepatide helped more participants reach key weight loss milestones, with manageable side effects and strong metabolic benefits.

12 May 2025

Tirzepatide outperforms semaglutide in weight loss clinical trial

Tirzepatide (trade name Zepbound) promoted greater weight loss in individuals with obesity than did semaglutide (trade name Wegovy) in a clinical trial that compared the safety and efficacy of the injectable drugs.

12 May 2025

GLP-1RAs show added protection against cancer beyond weight reduction

New research being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May) and published in the journal eClinicalMedicine finds that first generation weight-loss medications like liraglutide and exenatide appear to show anti-cancer benefits beyond weight loss.

11 May 2025

GLP-1 receptor agonists improve mood and metabolic health in adults with mental illness

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can lead to significant weight loss and improve blood sugar control in adults with severe mental illness, as well as having positive effects on mood, well-being, and quality of life in those both with and without mental illness, according to a systematic review of the available evidence being presented at this year's European Congress on Obesity (ECO) in Malaga, Spain (11-14 May).

11 May 2025

Semaglutide clears liver inflammation and cuts fibrosis in MASH patients, trial shows

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic dysfunction-associated steatohepatitis (MASH). The interim results also reveal meaningful weight loss and improved cardiometabolic markers, with a favorable safety profile.

4 May 2025

KFF Health News' 'What the Health?': 100 days of health policy upheaval

Members of Congress are back in Washington this week, and Republicans are facing hard decisions on how to reduce Medicaid spending, even as new polling shows that would be unpopular among their voters.

1 May 2025

High fructose diets impair brain function and appetite control, study shows

Review highlights how excessive fructose intake disrupts brain energy balance, appetite regulation, and cognitive function. Processed sources, such as sugary drinks, may overwhelm metabolic pathways and induce neuroinflammation, particularly during adolescence.

30 Apr 2025

Semaglutide shows promise in treating severe liver disease

Semaglutide effectively treats liver disease in two thirds of patients, new research has found.

30 Apr 2025

Vapourtec video showcases fully automated peptide synthesis

A recent video produced by Vapourtec highlights the patented automatic Variable Bed Flow Reactor (VBFR) demonstrating fully automated solid phase peptide synthesis.

30 Apr 2025

What’s behind Gen Z’s skepticism about Ozempic and Wegovy

A U.S. study of over 500 youth aged 14–24 found high awareness but widespread hesitation about using semaglutide for weight loss. Concerns focused on safety, social stigma, and a preference for lifestyle changes like diet and exercise.

24 Apr 2025

Body image concerns drive interest in GLP-1 weight loss drugs, study finds

A new study from Rutgers University links higher body dissatisfaction, BMI, and maladaptive weight loss behaviors with interest in GLP-1 medications for weight loss. Conversely, body appreciation appears to protect against this interest, especially in the face of potential side effects.

23 Apr 2025